A Massachusetts law that allows the state government to limit how pharmaceutical firms market their products to doctors could hamper clinical research and scare life sciences investors away, said John Lechleiter, Eli Lilly and Co.'s president and CEO. Physicians need to be informed about innovations from drugmakers and deserve compensation "for their valuable time," Lechleiter said.

Related Summaries